-+ 0.00%
-+ 0.00%
-+ 0.00%

Enveric net loss narrows to $1.6 million in Q1 FY26; loss per share improves to $1.08

PUBT·05/15/2026 12:01:20
Listen to the news
Enveric net loss narrows to $1.6 million in Q1 FY26; loss per share improves to $1.08
  • Enveric Biosciences posted a net loss attributable to stockholders of USD 1.6 million, narrowing from USD 2.2 million in first-quarter 2025, while loss per share improved to USD 1.08 from USD 14.58.
  • Cash on hand totaled USD 4.9 million, with USD 2.8 million of gross proceeds raised through offerings during the quarter.
  • As of May 15, 2026, cash balance was about USD 10.3 million following a private placement of up to USD 13.9 million including USD 5 million upfront, with USD 1.5 million raised from warrant exercises.
  • Management said funds are expected to support preclinical development for lead candidate EB-003, planned IND filing, operations into first quarter of fiscal 2027.
  • Recent updates included EB-003 receptor engagement assay data showing dual Gq and β-arrestin signaling at 5-HT2A, with additional preclinical results indicating rapid reduction in conditioned fear response in a PTSD model.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260515529130) on May 15, 2026, and is solely responsible for the information contained therein.